SYMLIN® Use Helped Patients with Type 2 or Type 1 Diabetes Achieve More Time in Normal Glucose Range
10:00 EDT 9 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from
new analyses of previously completed clinical studies demonstrating that
patients with type 2 or type 1 diabetes achieved a greater proportion of
blood glu...
Other Sources for this Article
Amylin Pharmaceuticals, Inc.
Alice Izzo
Phone:
858-642-7272
Cell: 858-232-9072
alice.izzo@amylin.com
More From BioPortfolio on "SYMLIN® Use Helped Patients with Type 2 or Type 1 Diabetes Achieve More Time in Normal Glucose Range"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
